A new analysis published in European Urology
suggests that the risk window of recurrence for surgically treated renal cell carcinoma (RCC) may be longer than previously thought. Hoping to provide new data for treatment and follow-up protocols, the study established the risk of recurrence at 5 years was equal to or higher than the risk of recurrence after 3 years. Marcus L. Jamil, MD, from the Vattikuti Urology Institute at the Henry Ford Health System
in Detroit, hopes these results will encourage health providers to continue monitoring beyond 5 years.
Learn more by clicking here.